Particle.news
Download on the App Store
12 ARTICLES
·
last yr.

FDA's Preliminary Review Finds No Link Between Ozempic, Wegovy and Suicidal Thoughts

Despite the initial findings, the FDA continues to investigate due to the possibility of a small risk.

Image
WHITE OAK, MD - JULY 20: A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Photo by Sarah Silbiger/Getty Images)
Image
Image

Overview

  • FDA's preliminary review finds no evidence that drugs like Ozempic and Wegovy cause suicidal thoughts or actions.
  • Despite the preliminary findings, the FDA cannot definitively rule out that a small risk may exist.
  • The review follows a recent federally funded study that showed people taking semaglutide, the medication in Ozempic and Wegovy, had a lower risk of suicidal thoughts than those taking other drugs to treat obesity and diabetes.
  • The FDA is analyzing reports related to more than a dozen drugs approved since 2005 that are known as GLP-1 receptor agonists.
  • Patients taking the drugs should report any concerns to health care providers, the FDA said.